Wilfrido Coronell-Rodríguez

Effectiveness of the monovalent rotavirus vaccine in Colombia: A case-control study

OBJECTIVE To assess the effectiveness of the monovalent rotavirus vaccine (RV1) to prevent rotavirus diarrhea admissions to emergency departments (ED) in Colombia. METHODS A multicenter case-control study was carried out in six Colombian cities from 2011 to January, 2013. Cases were laboratory confirmed rotavirus diarrhea patients admitted to ED of selected health centers. Controls were patients with non-rotavirus diarrhea. Vaccination status was card-confirmed. Vaccine effectiveness and 95% confidence intervals (CI) were calculated from the conditional logistic regression models using the formula 1-adjusted odds ratio×100. RESULTS 1051 fecal samples were collected from 193 cases and 858 controls. Vaccination history was confirmed on 173 cases (90%) and 801 controls (93%). Among the rotavirus-positive samples with vaccination history, 57% were G2P[4], 9.8% G9P[8], 6% G9P[6]. Median age of cases (17 months) was greater than controls (15 months) (P<0.001), and mothers of cases had lower level of education (P=0.025). The adjusted effectiveness was 79.19% (95% CI, 23.7 to 94.32) among children 6-11 months of age and -39.75% (95% CI, -270.67 to 47.24) among those >12 months of age. Against overnight rotavirus hospitalizations, RV1 provided protection of 84.42% (95% CI, 22.68 to 96.86) among children 6-11 months of age, and -79.49% (95% CI, -555.8 to 51.08) among those >12 months. CONCLUSIONS RV1 provided significant protection against rotavirus hospitalization among children under 1 year of age in the Colombian setting. The observation of lower effectiveness in children >12 months requires further assessment.

Treatment costs of diarrheal disease and all-cause pneumonia among children under-5 years of age in Colombia.

OBJECTIVE We estimate treatment costs associated with diarrheal disease and all-cause pneumonia among children under-5 years of age in Colombia and assess similarities or differences with previous cost estimations in developing countries of the Americas. METHODS Macro-costing methods were used to carry out an analysis of diarrhea and all-cause pneumonia costs in Colombia in 2010. The perspective of the health care system was taken. Data were extracted from a health insurer database that includes information on health service utilization among 130,800 children from low-income households. Lengths of stay for hospital admissions and frequencies of cases at all levels of care registered in the database were estimated. RESULTS There were 1456 diarrheal disease cases among the 130,800 children (aged ≥ 60 months) included in the study. The median cost per case was

Costos de otitis media aguda en pediatría, en una ciudad de la Costa Caribe colombiana

27.10 (interquartile range [IQR]:

Interpretive Reading of the Antibiogram: A Tool for Clinical Practice

15.60-77.40). A total of 1545 all-cause pneumonia cases were reported to the insurer in 2010, resulting in a frequency of 1181 cases per 100,000 children (95% confidence interval [CI]=1122, 1240). The overall cost of all-cause pneumonia cases was

Infección por virus del Zika en el embarazo, impacto fetal y neonatal

858,791, and the median cost per case treated was

Effect of rotavirus vaccine on childhood diarrhea mortality in five Latin American countries.

263 (IQR:

Estimating costs associated with a community outbreak of meningococcal disease in a colombian Caribbean city.

27-546). Comparisons by level of care showed that costs were significantly different for the two diseases (p<.05). Costs for the diseases did not differ by age group (p>.05). CONCLUSIONS Diarrhea and all-cause pneumonia constitute a significant economic and health burden in Colombia. The relatively large size of our sample allowed us to provide reliable national estimates of the costs associated with these diseases. Our results for Colombia are similar to previous estimates from developing countries in the Americas. These data provide valid estimates that may be used decision makers in other countries to make appropriate recommendations on the introduction of rotavirus and pneumococcal vaccines.

Endocarditis infecciosa derecha como primera manifestación de leucemia linfoblástica aguda en niños

Introduction: Acute otitis media is the main cause of visits or medical consultations, antibiotic use and outpatient surgeries in developed countries and is associated with a significant economic burden; However, the non-medical indirect costs of AOM, which are relevant in this pathology, have been underestimated Objective: To estimate the costs of AOM in pediatric patients in Cartagena Colombia. Materials and methods: Prospective study of microcosteo from 2014 to 2015. The direct and indirect costs of AOM were determined through forms applied to parents or caregivers. Loss of productivity was estimated based on the monthly legal minimum wage of 2014 (COP

Clinical and Epidemiological Profile of the Chikungunya and Zika Outbreak in Neonates 2014-2016, Cartagena-Colombia

616.000) (USD

Effectiveness of Pneumococcal Conjugate Vaccine PCV10 in a City of the Colombian Caribbean: Case-Control Study Nested in a Cohort

308). Results: A total of 62 episodes of AOM were present. Total economic costs attributed per OMA episode were COP